Effect of the dipeptidyl peptidase-4 inhibitor linagliptin on atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits: iMap-IVUS and pathological analysis
| Autor: | Hironori Haruta, Takafumi Kurosawa, Kazuhiro Hagikura, Yuxin Li, Yasuo Okumura, Tadateru Takayama, Masashi Shiomi, Atsushi Hirayama, Taro Matsumoto, Hiroyuki Hao, Takafumi Hiro, Mitsumasa Sudo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Urology Hyperlipidemias Linagliptin Dipeptidyl peptidase-4 inhibitor 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Diabetes mellitus medicine.artery Intravascular ultrasound medicine Brachiocephalic artery Animals 030212 general & internal medicine Pathological Ultrasonography Interventional Dipeptidyl-Peptidase IV Inhibitors medicine.diagnostic_test business.industry Ultrasound medicine.disease Atherosclerosis Lipids Cardiac surgery Femoral Artery Disease Models Animal Treatment Outcome Rabbits Cardiology and Cardiovascular Medicine business Biomarkers medicine.drug |
| Zdroj: | Heart and vessels. 36(1) |
| ISSN: | 1615-2573 |
| Popis: | Dipeptidyl peptidase-4 (DPP-4) inhibitors have potential as a treatment for atherosclerosis. However, it is unclear whether DPP-4 inhibitors stabilize atherosclerotic plaque or alter the composition of complex plaque. Sixteen Watanabe heritable hyperlipidemic rabbits aged 10–12 weeks with atherosclerotic plaque in the brachiocephalic artery detected by iMap™ intravascular ultrasound (IVUS) were divided into a DPP-4 inhibitor group and a control group. Linagliptin was administered to the DPP-4 inhibitor group via nasogastric tube at a dose of 10 mg/kg/day for 16 weeks, and control rabbits received the same volume of 0.5% hydroxyethylcellulose. After evaluation by IVUS at 16 weeks, the brachiocephalic arteries were harvested for pathological examination. IVUS revealed that linagliptin significantly reduced the plaque volume and vessel volume (control group vs. DPP-4 inhibitor group: ∆plaque volume, 1.02 ± 0.96 mm3 vs. − 3.59 ± 0.92 mm3, P = 0.004; ∆vessel volume, − 1.22 ± 2.36 mm3 vs. − 8.66 ± 2.33 mm3, P = 0.04; %change in plaque volume, 6.90 ± 5.62% vs. − 15.06 ± 3.29%, P = 0.005). With regard to plaque composition, linagliptin significantly reduced the volume of fibrotic, lipidic, and necrotic plaque (control group vs. DPP-4 inhibitor group: ∆fibrotic volume, 0.56 ± 1.27 mm3 vs. − 5.57 ± 1.46 mm3, P = 0.04; ∆lipidic volume, 0.24 ± 0.24 mm3 vs. − 0.42 ± 0.16 mm3 P = 0.04; ∆necrotic volume, 0.76 ± 0.54 mm3 vs. − 0.84 ± 0.25 mm3, P = 0.02). Pathological examination did not show any significant differences in the %smooth muscle cell area or %fibrotic area, but infiltration of macrophages into plaque was reduced by linagliptin treatment (%macrophage area: 12.03% ± 1.51% vs. 7.21 ± 1.65%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink